UOC
RVNC icon

UBS O'Connor’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS O'Connor’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$38K – 743
2022
Q4 		$38K Hold
100,000
– – ﹤0.01% 678
2022
Q3 		$48K Hold
100,000
– – ﹤0.01% 862
2022
Q2 		$125K Hold
100,000
– – ﹤0.01% 852
2022
Q1 		$250K Buy
+100,000
New +$1.52M ﹤0.01% 769

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

UBS O'Connor's RVNC Position: Q3 2024 in Review

UBS O'Connor sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 325,314 shares — an estimated $836K sold.

UBS O'Connor first reported a position in RVNC in Q1 2022 and held it in 9 quarters. The position peaked at $2.73M in Q3 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • UBS O'Connor reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 325,314 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $836K.
  • UBS O'Connor first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 9 quarters.
  • UBS O'Connor's Revance Therapeutics, Inc. position peaked at $2.73M in Q3 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.